Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind trial of 9-valent HPV vaccine versus Gardasil in men aged 16 to 26 years
2013-003399-10Phase 3Completed
- Sponsor
- Sanofi Pasteur MSD S.N.C.
- Start
- Dec 2013
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of recombinant human papillomavirus 9-valent vaccine and qHPV vaccine in human papillomavirus infection, anogenital warts, Cervical Cancer (CC) and 3 more (2 arms), sponsored by Sanofi Pasteur MSD S.N.C. Primary endpoint: cLIA geometric mean titres to HPV 6, 11, 16, and 18. Started Dec 2013; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccineqHPV vaccine
03
Conditions
human papillomavirus infectionanogenital wartsCervical Cancer (CC)vulvar intraepithelial neoplasia (VIN)vaginal intraepithelial neoplasia (VAIN)
Beyond the preview
Go deeper on 2013-003399-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003399-10.